05:57:06 EST Mon 16 Dec 2019
Enter Symbol
or Name
USA
CA



Login ID:
Password:
Save

Allergan Declares Third Quarter 2019 Cash Dividend of $0.74 Per Ordinary Share

2019-07-19 07:30 ET - News Release

- Dividend to be Paid on September 13, 2019 -
- Record Date of August 13, 2019 -

DUBLIN, July 19, 2019 /PRNewswire/ -- Allergan plc (NYSE: AGN) today announced that its Board of Directors has declared a cash dividend of $0.74 per ordinary share for the third quarter of 2019. The dividend will be paid on September 13, 2019 to shareholders of record at the close of business on August 13, 2019.

About Allergan plc

Allergan plc (NYSE: AGN), headquartered in Dublin, Ireland, is a global pharmaceutical leader focused on developing, manufacturing and commercializing branded pharmaceutical, device, biologic, surgical and regenerative medicine products for patients around the world. Allergan markets a portfolio of leading brands and best-in-class products primarily focused on four key therapeutic areas including medical aesthetics, eye care, central nervous system and gastroenterology. As part of its approach to delivering innovation for better patient care, Allergan has built one of the broadest pharmaceutical and device research and development pipelines in the industry.

With colleagues and commercial operations located in approximately 100 countries, Allergan is committed to working with physicians, healthcare providers and patients to deliver innovative and meaningful treatments that help people around the world live longer, healthier lives every day.

For more information, visit Allergan's website at www.Allergan.com.

Forward-Looking Statement

Statements contained in this press release that refer to future events or other non-historical facts are forward-looking statements that reflect Allergan's current perspective on existing trends and information as of the date of this release. Actual results may differ materially from Allergan's current expectations depending upon a number of factors affecting Allergan's business. These factors include, among others, the difficulty of predicting the timing or outcome of FDA approvals or actions, if any; the impact of competitive products and pricing; market acceptance of and continued demand for Allergan's products; the impact of uncertainty around timing of generic entry related to key products, including RESTASIS®, on our financial results; risks associated with divestitures, acquisitions, mergers and joint ventures; risks related to impairments; uncertainty associated with financial projections, projected cost reductions, projected debt reduction, projected synergies, restructurings, increased costs, and adverse tax consequences; difficulties or delays in manufacturing; and other risks and uncertainties detailed in Allergan's periodic public filings with the Securities and Exchange Commission, including but not limited to Allergan's Annual Report on Form 10-K for the year ended December 31, 2018 and Allergan's Quarterly Report on Form 10-Q for the period ended March 31, 2019. Except as expressly required by law, Allergan disclaims any intent or obligation to update these forward-looking statements.

CONTACTS:      

Allergan:
Investors:
Manisha Narasimhan, PhD
(862) 261-7162

Media:
Lisa Brown
(862) 261-7320

© 2019 Canjex Publishing Ltd. All rights reserved.